A self-augmenting gene expression cassette for enhanced and sustained transgene expression in the presence of proinflammatory cytokines.

Viral promoters can yield high gene expression levels yet tend to be attenuated in vivo by host proinflammatory cytokines. Prolonged transgene expression can be obtained using constitutive cellular promoters. However, levels of transgene expression driven by cellular promoters are insufficient for effective therapy. We designed a novel self-augmenting gene expression cassette in which the transgene product can induce an endogenous transcription factor to enhance the activity of a weak cellular promoter driving its expression. Using the cellular major histocompatibility complex class I (H-2K(b)) promoter to drive the interferon (IFN-gamma) cytokine gene, we show that the H-2K(b) promoter, although exhibiting much lower basal activity, yields higher IFN-gamma production than the CMV promoter 2 days after transfection. IFN-gamma expression driven by the H-2K(b) promoter also lasts longer than that driven by the cytomegalovirus promoter. Our data demonstrate that the self-augmenting strategy provides a promising approach to achieve high and sustained transgene expression in vivo.

[1]  T. Tsang,et al.  Novel amplifier expression vectors producing higher levels of IL-2 led to slower tumor growth and longer survival in vivo. , 2005, DNA and cell biology.

[2]  D. Wells,et al.  Gene Therapy Progress and Prospects: Electroporation and other physical methods , 2004, Gene Therapy.

[3]  G. Rubanyi,et al.  Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle , 2004, The journal of gene medicine.

[4]  T. Tsang,et al.  A novel inducible amplifier expression vector for high and controlled gene expression. , 2004, International journal of molecular medicine.

[5]  R. Flavell,et al.  The activation of major histocompatibility complex class I genes by interferon regulatory factor-1 (IRF-1) , 2004, Immunogenetics.

[6]  C. Higgins,et al.  Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter , 2001, Gene Therapy.

[7]  M. Kurimoto,et al.  IFN‐α  and IL‐18 synergistically enhance IFN‐γ  production in human NK cells: differential regulation of Stat4 activation and IFN‐γ  gene expression by IFN‐α  and IL‐12 , 2001 .

[8]  Leaf Huang,et al.  Systemic production of IL‐12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo , 2001, The journal of gene medicine.

[9]  J. Ellis,et al.  Silencing of gene expression: implications for design of retrovirus vectors , 2001, Reviews in medical virology.

[10]  S. Cheng,et al.  High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  G. Rubanyi,et al.  The future of human gene therapy. , 2001, Molecular aspects of medicine.

[12]  H. Herweijer,et al.  Time course of gene expression after plasmid DNA gene transfer to the liver , 2001, The journal of gene medicine.

[13]  J. Dausset,et al.  A Specific Interferon (IFN)-stimulated Response Element of the Distal HLA-G Promoter Binds IFN-regulatory Factor 1 and Mediates Enhancement of This Nonclassical Class I Gene by IFN-β* , 2001, The Journal of Biological Chemistry.

[14]  M. Kaleko,et al.  Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  M. Jaroszeski,et al.  Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. , 2001, DNA and cell biology.

[16]  R. Jaenisch,et al.  Retroviral Expression in Embryonic Stem Cells and Hematopoietic Stem Cells , 2000, Molecular and Cellular Biology.

[17]  M. Stedman,et al.  Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. , 1999, Human gene therapy.

[18]  E. Coccia,et al.  Synergistic stimulation of MHC class I and IRF‐1 gene expression by IFN‐γ and TNF‐α in oligodendrocytes , 1998, The European journal of neuroscience.

[19]  P. Morris,et al.  Identification and Regulation of Testicular Interferon-γ (IFNγ) Receptor Subunits: IFNγ Enhances Interferon Regulatory Factor-1 and Interleukin-1β Converting Enzyme Expression. , 1998, Endocrinology.

[20]  F. Paillard.  Advantages of Non-Human Adenoviruses Versus Human Adenoviruses Promoter Attenuation in Gene Therapy: Causes and Remedies , 1997 .

[21]  M. Imperiale,et al.  Promoter Attenuation in Gene Therapy: Interferon-γ and Tumor Necrosis Factor-α Inhibit Transgene Expression , 1997 .

[22]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[23]  M. Lusky,et al.  Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. , 1997, Immunology letters.

[24]  S. Piscitelli,et al.  Pharmacokinetic Studies with Recombinant Cytokines , 1997, Clinical pharmacokinetics.

[25]  R. Doll,et al.  Comparison of promoter strengths on gene delivery into mammalian brain cells using AAV vectors. , 1996, Gene therapy.

[26]  K. Becker,et al.  NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[27]  G. Splitter,et al.  Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. , 1995, Human gene therapy.

[28]  S. Landolfo,et al.  Interferon-α Inhibits the Murine Cytomegalovirus Immediate-Early Gene Expression by Down-Regulating NF-κB Activity , 1995 .

[29]  M. Kay,et al.  Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. , 1995, Gene therapy.

[30]  R. Scharfmann,et al.  Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Israël,et al.  Detailed analysis of the mouse H-2Kb promoter: Enhancer-like sequences and their role in the regulation of class I gene expression , 1986, Cell.

[32]  P. Brouckaert,et al.  Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase–dependent manner , 2009, The Journal of experimental medicine.